Consensus RenovoRx, Inc.

Equities

RNXT

US75989R1077

Market Closed - Nasdaq Other stock markets 02:00:01 11/05/2024 am IST			5-day change	1st Jan Change
1.45 ^USD	+7.81%		+18.85%	-36.68%

16/04	RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting	CI
15/04	RenovoRx, Inc. announced that it has received $11.136652 million in funding	CI

Evolution of the average Target Price on RenovoRx, Inc.

Price target over the last 5 years

History of analyst recommendation changes

9fb67e173808d2c3d3c943b91b75.GxbdfeGiwGLA3HZBVBeCqmZyCzcxCUyTANCMkDIlDC8.RHGbSKzqhDSvvjgrEmS02DkiP25USwThMaLb1XEVSmMjYbcZtO-5Jpe_Ow~c1bc9f04cd170be85112cdceaa915b81

Analyst Recommendations on RenovoRx, Inc.

Alliance Global Starts RenovoRx With Buy Rating, $4 Price Target	02/02	MT
Maxim Downgrades RenovoRx to Hold From Buy	15/11	MT
Roth MKM Adjusts Price Target on RenovoRx to $13 From $14, Maintains Buy Rating	18/23/18	MT
Roth Capital Starts RenovoRx at Buy With $16 Price Target	01/21/01	MT
RENOVORX : Maxim Starts RenovoRx at Buy with $15 Price Target	06/21/06	MT
RenovoRx : Files for IPO, Sets Target Price of $11-$13/Unit	20/21/20	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.45 USD

Average target price

3.75 USD

Spread / Average Target

+158.62%

High Price Target

4 USD

Spread / Highest target

+175.86%

Low Price Target

3.5 USD

Spread / Lowest Target

+141.38%

Consensus detail

Consensus revision (last 18 months)

Analysts covering RenovoRx, Inc.

Alliance Global Partners
Maxim
Roth MKM
Roth Capital Partners

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar